913718-34-0

Basic information

• Product Name: (4aS,9aR)-4,4a,9,9a-tetrahydro-Indeno[2,1-b]-1,4-oxazin-3(2H)-one
• Synonyms: (4aS,9aR)-4,4a,9,9a-tetrahydro-Indeno[2,1-b]-1,4-oxazin-3(2H)-one
• CAS NO: 913718-34-0
• Molecular Formula: C₁₁H₁₁NO₂
• Molecular Weight: 189.21054
• Mol File: 913718-34-0.mol

Chemical Properties

• Boiling Point: 433.2±45.0 °C(Predicted)
• Appearance: /
• Density: 1.228±0.06 g/cm3(Predicted)
• PKA: 13?+-.0.20(Predicted)
• CAS DataBase Reference: (4aS,9aR)-4,4a,9,9a-tetrahydro-Indeno[2,1-b]-1,4-oxazin-3(2H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: (4aS,9aR)-4,4a,9,9a-tetrahydro-Indeno[2,1-b]-1,4-oxazin-3(2H)-one(913718-34-0)
• EPA Substance Registry System: (4aS,9aR)-4,4a,9,9a-tetrahydro-Indeno[2,1-b]-1,4-oxazin-3(2H)-one(913718-34-0)

Safety Data

• Hazardous Substances Data: 913718-34-0(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry Research:
(4aS,9aR)-4,4a,9,9a-tetrahydro-Indeno[2,1-b]-1,4-oxazin-3(2H)-one is utilized as a research compound for exploring its pharmacological properties and potential applications in the development of new drugs. Its specific biological activity and molecular targets within the body need to be further investigated to understand its full potential.
Used in Drug Development:
In the pharmaceutical industry, (4aS,9aR)-4,4a,9,9a-tetrahydro-Indeno[2,1-b]-1,4-oxazin-3(2H)-one serves as a lead compound for the design and synthesis of novel therapeutic agents. Its complex molecular structure and potential interactions with biological targets make it a valuable candidate for creating new medications to treat various diseases and conditions.
Additional research and studies are essential to fully comprehend the potential uses and implications of (4aS,9aR)-4,4a,9,9a-tetrahydro-Indeno[2,1-b]-1,4-oxazin-3(2H)-one in different applications. As our understanding of its properties and interactions grows, so too will the range of possible applications in various industries.

Upstream product

• 7480-35-5 (1S,2R)-1-amino-2-indanol 
• 105-39-5 chloroacetic acid ethyl ester 

Downstream Products

• 1360651-94-0 C₁₉H₁₈N₃O⁽¹⁺⁾*Cl^(1-) 
• 1384865-99-9 C₂₀H₂₀N₃O₂⁽¹⁺⁾*Cl^(1-) 
• 955378-07-1 C₂₀H₂₃N₃O*ClH 
• 903571-02-8 (5aR,10bS)-5a,10b-dihydro-2-(2,4,6-trimethylphenyl)-4H,6H-indeno[2,1-b]-1,2,4-triazolo[4,3-d]-1,4-oxazinium chloride 
• 1374694-45-7 (5aR,10bS)-2-(2,6-dichlorophenyl)-4,5a,6,10b-tetrahydro-2H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazin-11-ium tetrafluoroborate 

Relevant articles and documents

Catalytic enantioselective Steglich rearrangements using chiral N-heterocyclic carbenes

The evaluation of a range of enantiomerically pure NHCs, prepared in situ from imidazolinium or triazolium salt precatalysts, to promote the catalytic enantioselective Steglich rearrangement of oxazolyl carbonates to their C-carboxyazlactones, is reported. Modest levels of enantioselectivity (up to 66% ee) are observed using oxazolidinone derived NHCs.

FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS

A series of 5,6-dihydro-l,3-benzothiazol-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PD kinase enzymes, are accordingly of b.enefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.